ArticleTranslational cancer research2026
DDR1 in esophageal squamous cell carcinoma: bioinformatics discovery and experimental validation.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Esophageal squamous cell carcinoma accounts for almost 90% of all esophageal cancer cases. Recent progress in understanding tumor biology, early diagnosis, and surgical techniques has contributed to the improvements in incidence and mortality. However, the discovery of novel biomarkers remains essential for further reducing disease burden and improving clinical outcomes. The study focuses on investigating the function of DDR1 and its potential clinical utility as a biomarker in esophageal squamous cell carcinoma (ESCC). Methods: Five gene expression datasets were included in the study, and a meta-analysis of differentially expressed genes (DEGs) was conducted. Genes identified by three feature selection algorithms were intersected and used for predictive modeling and experimental validation. Clinical validation included reverse transcription quantitative polymerase chain reaction (RT-qPCR) on 40 paired ESCC tumors and adjacent tissues. TE-7 ESCC cells were transfected with anti-miR-199a-5p or pre-miR-199a-5p and analyzed by RT-qPCR and western blotting. Results: DDR1 was significantly upregulated across datasets [pooled average log fold change (FC) =1.06, pooled P<0.05]. A generalized linear model trained using the gene exhibited good performance in classifying tumor and non-tumor samples across four external validation sets. In 40 paired clinical samples, RT-qPCR revealed significantly higher DDR1 and lower miR-199a-5p levels in tumors compared to non-tumor samples (both P<0.001). Anti-miR-199a-5p produced a significant reduction in miR-199a-5p (P=0.041) and a significant increase in DDR1 (P=0.01). MiR-199a-5p inhibition increased DDR1, STAT3, pSTAT3, mesenchymal markers [N-cadherin (CDH2), vimentin (VIM)], and decreased epithelial marker [E-cadherin (CDH1)]. The opposite pattern was observed following miR-199a-5p overexpression (all P<0.05). Conclusions: DDR1 is a candidate biomarker for ESCC. Modulating miR-199a-5p alters DDR1, STAT3 activation, and epithelial-mesenchymal transition (EMT) marker profiles, making miR-199a-5p/DDR1/STAT3/EMT pathway a potential therapeutic target in ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.